In the past, medicinal chemists have been asked only to advance new molecular entities to clinical development with acceptable physical properties for formulation. But today's more complex APIs need advanced formulation science.
Characterizing physical properties is not business-as-usual for chemists. And because the disciplines of characterizing chemical and physical properties tend to be separated along the development timeline between API chemists and formulators, there is often an imperfect understanding of each other's problems and solutions.
This is why it behooves developers to bring these parties together early on to examine and mitigate risks. Read how in the latest Patheon whitepaper.